Neupogen (Filgrastim)

Filgrastim, the active ingredient in Neupogen, is a granulocyte colony-stimulating factor (G‑CSF) presented as a injectable solution for intravenous and subcutaneous use. It treats chemotherapy‑induced neutropenia and other neutropenia conditions in patients undergoing cancer therapy, bone marrow transplantation, or with chronic neutropenia.

GNH USA supplies Neupogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Neupogen is a granulocyte colony‑stimulating factor used to manage neutropenia in several clinical settings.

Chemotherapy‑induced neutropenia: reduces the duration of low neutrophil counts and helps maintain chemotherapy dose intensity. Neutropenia associated with bone marrow transplantation: supports engraftment and accelerates neutrophil recovery. Severe chronic neutropenia: increases neutrophil production to lower infection risk. Peripheral blood stem cell mobilization: enhances stem cell yield for collection prior to transplantation.

Neupogen may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Bone pain: aching discomfort often reported in long bones. - Injection site reactions: redness, swelling, or mild bruising. - Fever: low‑grade temperature elevations. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Splenic rupture: sudden abdominal pain requiring urgent care. - Acute respiratory distress syndrome (ARDS): severe breathing difficulty. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Capillary leak syndrome: hypotension and edema.

Neupogen requires careful monitoring and specific safety measures.

Monitor blood counts: perform regular CBCs to assess neutrophil response. Assess for splenomegaly: evaluate spleen size before and during therapy. Use caution in sickle cell disease: risk of vaso‑occlusive crises. Avoid in patients with known hypersensitivity to filgrastim or excipients. Pregnancy and lactation: weigh benefits against potential risks; consult a specialist. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Filgrastim can interact with other agents that affect bone marrow or immune function.

Major Interactions (Avoid): - Concurrent myelosuppressive chemotherapy: may prolong neutropenia. - High‑dose corticosteroids: can blunt neutrophil response. - Bone‑marrow‑suppressing antibiotics (e.g., chloramphenicol): additive suppression.

Moderate Interactions (Monitor Closely): - Cytokine‑modulating agents (e.g., interferon): may alter efficacy. - Immunosuppressants (e.g., cyclosporine): monitor neutrophil counts. - Live vaccines: potential for altered immune response.